PUBLISHER: DelveInsight | PRODUCT CODE: 1083581
PUBLISHER: DelveInsight | PRODUCT CODE: 1083581
DelveInsight's, 'congenital Adrenal Hyperplasia (CAH) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of congenital adrenal hyperplasia (CAH) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
According to National Organization for Rare Disorders, congenital adrenal hyperplasia (CAH) is a group of rare inherited autosomal recessive disorders characterized by a deficiency of one of the enzymes needed to make specific hormones. CAH affects the adrenal glands located at the top of each kidney. Normally, the adrenal glands are responsible for producing three different hormones: corticosteroids, mineralocorticoids, and androgens.
An enzyme deficiency will make the body unable to produce one or more of these hormones, resulting in the overproduction of another type of hormone precursor to compensate for the loss.
The most common cause of CAH is the absence of the enzyme 21-hydroxylase. Different mutations in the gene responsible for 21-hydroxylase result in different enzyme levels, producing a spectrum of effects. CAH due to 21-hydroxylase deficiency is responsible for 95% of all cases of CAH and is broken down further into two subcategories: classical CAH, which can be sub-divided into the salt-losing form or the simple-virilizing form, and non-classical CAH. Classical CAH is by far the more severe form and can result in adrenal crisis and death if not detected and treated. Non-classical CAH is milder and may or may not present symptoms. Since the absence of 21-hydroxylase makes the individuals unable to make the hormone cortisol and, in the case of salt-losing CAH, aldosterone, the body produces more androgens which cause a variety of symptoms, such as abnormal genital development in infant girls. There are other much rarer forms of CAH as well, including 11-Beta hydroxylase deficiency, 17a-hydroxylase deficiency, 3-Beta-hydroxysteroid dehydrogenase deficiency, congenital lipoid adrenal hyperplasia, and p450 oxidoreductase deficiency which all present different symptoms. Although CAH is not curable, as long as patients receive adequate care and treatment, they can go on to lead normal lives.
The goal of medical treatment of CAH differs by the patient's age. CAH is a recessive gene, so both the mother and father must be recessive carriers. Couples with recessive CAH genes may prevent CAH through preimplantation genetic diagnosis.
The congenital adrenal hyperplasia (CAH) epidemiology division provides insights into the historical and current patient pool, along with the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
The disease epidemiology covered in the report provides historical and forecasted congenital adrenal hyperplasia (CAH) epidemiology segmented as the Diagnosed Prevalence of Congenital Adrenal Hyperplasia, Age-specific cases of Congenital Adrenal Hyperplasia, Mutation based cases of Congenital Adrenal Hyperplasia, and Type-specific cases of Congenital Adrenal Hyperplasia. The report includes the prevalent scenario of Congenital Adrenal Hyperplasia (CAH) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
The epidemiology segment also provides the congenital adrenal hyperplasia (CAH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total diagnosed population of congenital adrenal hyperplasia (CAH) in the 7MM countries was close to 73,000 cases in 2021.
As per the estimates, the United States had the highest diagnosed prevalence of congenital adrenal hyperplasia (CAH) population in 2021. Among the EU5 countries, Germany had the highest diagnosed prevalent population of congenital adrenal hyperplasia (CAH) with nearly 8,000 cases, followed by France in 2021. On the other hand, Spain had the lowest diagnosed prevalent population of close to 4,300 cases in 2021.
We interview KOLs and obtain SME's opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.
Study Period: 2019-2032.